Literature DB >> 9517388

Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel.

V Chappe1, Y Mettey, J M Vierfond, J W Hanrahan, M Gola, B Verrier, F Becq.   

Abstract

1. On the basis of their structure, we compared the ability of 35 xanthine derivatives to activate the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel stably expressed in chinese hamster ovary (CHO) cells using the cell-attached patch clamp and iodide efflux techniques. 2. Activation of CFTR channels was obtained with 3-mono, 1,3-di or 1,3,7-tri-substituted alkyl xanthine derivatives (enprofylline, theophylline, aminophylline, IBMX, DPMX and pentoxifylline). By contrast, xanthine derivatives substituted at the C8- or N9-position failed to open CFTR channels. 3. The CFTR chloride channel activity was blocked by glibenclamide (100 microM) but not by DIDS (100 microM). 4. Activation of CFTR by xanthines was not mimicked by the calcium ionophore A23187, adenosine, UTP, ATP or the specific phosphodiesterase inhibitors rolipram, Ro 20-1724 and milrinone. In addition, we found no correlation between the effect of xanthines on CFTR and on the cellular cyclic AMP or ATP levels. 5. We then synthesized a series of 3,7-dimethyl-1-alkyl xanthine derivatives; among them, 3,7-dimethyl-1-propyl xanthine and 3,7-dimethyl-1-isobutyl xanthine both activated CFTR channels without increasing the intracellular cyclic AMP level, while the structurally related 3,7-dimethyl-1-(2-propenyl) xanthine and 3,7-dimethyl-1-(oxiranyl methyl) xanthine were inactive. 6. Our findings delineate a novel function for xanthine compounds and identify the molecular features that enable xanthine activation of CFTR. These results may be useful in the development of new molecules for studying the pharmacology of chloride channels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517388      PMCID: PMC1565206          DOI: 10.1038/sj.bjp.0701648

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.

Authors:  Ori Kalid; Martin Mense; Sharon Fischman; Alina Shitrit; Hermann Bihler; Efrat Ben-Zeev; Nili Schutz; Nicoletta Pedemonte; Philip J Thomas; Robert J Bridges; Diana R Wetmore; Yael Marantz; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-10-26       Impact factor: 3.686

2.  C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation.

Authors:  Arnaud Billet; Patricia Melin; Mathilde Jollivet; Jean-Paul Mornon; Isabelle Callebaut; Frédéric Becq
Journal:  J Biol Chem       Date:  2010-04-30       Impact factor: 5.157

3.  Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.

Authors:  Theresa A Laguna; Cavan S Reilly; Cynthia B Williams; Cole Welchlin; Chris H Wendt
Journal:  Pediatr Pulmonol       Date:  2015-06-26

4.  Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs.

Authors:  X Jiang; L Y Lim; J W Daly; A H Li; K A Jacobson; M Roberge
Journal:  Int J Oncol       Date:  2000-05       Impact factor: 5.650

5.  Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells.

Authors:  Diana R Wetmore; Elizabeth Joseloff; Joseph Pilewski; Douglas P Lee; Kay A Lawton; Matthew W Mitchell; Michael V Milburn; John A Ryals; Lining Guo
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

6.  Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004.

Authors:  R Dérand; L Bulteau-Pignoux; F Becq
Journal:  J Membr Biol       Date:  2003-07-15       Impact factor: 1.843

7.  Negative regulation of CFTR activity by extracellular ATP involves P2Y2 receptors in CFTR-expressing CHO cells.

Authors:  B Marcet; V Chappe; P Delmas; M Gola; B Verrier
Journal:  J Membr Biol       Date:  2003-07-01       Impact factor: 1.843

8.  General anesthetic octanol and related compounds activate wild-type and delF508 cystic fibrosis chloride channels.

Authors:  Brice Marcet; Frédéric Becq; Caroline Norez; Patrick Delmas; Bernard Verrier
Journal:  Br J Pharmacol       Date:  2004-02-16       Impact factor: 8.739

9.  Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease.

Authors:  Murali K Yanda; Qiangni Liu; Valeriu Cebotaru; William B Guggino; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

10.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.